CADTH has received notice of pending submissions from Takeda Canada for vedolizumab (Entyvio) for patients with inflammatory bowel disease (ulcerative colitis and Crohn's disease). For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website. Note that only patient groups may submit input.

For more details, go to: http://www.cadth.ca/en/products/cdr/patient-group-input-form/400